EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY-NC 4.0

Early and Sustained Shift in Headache Day Frequency Following Eptinezumab Treatment in Adults With Migraine for Whom 2–4 Previous Preventive Treatments Have Failed: A Post Hoc Analysis of the Randomized DELIVER Trial

Cristina Tassorelli iD, Amaal J Starling iD, Susanne F Awad iD, Xin Ying Lee iD, Line Pickering Boserup iD, Divya Asher iD, Seema Soni-Brahmbhatt iD, Bjørn Sperling, Peter J Goadsby iD

European Journal of Neurology · 2025

DOI: 10.1111/ene.70460 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift European Journal of Neurology, 2025. Verfasst von Cristina Tassorelli und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Brain and Behavioural Sciences, University of Pavia, Pavia, Italy. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Migraine Disorders. Die Arbeit nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: H. Lundbeck A/S.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

This post hoc analysis examined the reduction in monthly headache days ( MHDs ) by frequency category shifts and associated improvements following eptinezumab treatment.

Methods

The DELIVER trial evaluated eptinezumab in adults with migraine for whom 2–4 previous preventive treatments failed. During a 24‐week, double‐blind, placebo‐controlled period followed by a 48‐week extension period, participants received IV eptinezumab 100 mg, 300 mg, or placebo every 12 weeks, with all receiving eptinezumab beginning Week 25 (dose‐blinded). Participants were categorized by MHD frequency: > 14, 8–14, 4 to < 8, 1 to < 4, 0. MHD category shifts were evaluated in the total population and several subgroups (including participants with > 14 baseline MHDs and early ≥ 50% responders). In participants reporting < 8 MHDs after all doses, the associated changes in headache intensity and disease status were evaluated.

Results

Of randomized participants, 88% (782/890) completed the trial. The percentage of participants randomized initially to eptinezumab who reported < 4 MHDs was 23% (138/592) over Weeks 1–12 and 47% (236/498) over Weeks 61–72; 9% reported 0 MHDs after the final dose. Of participants randomized initially to eptinezumab who shifted from ≥ 8 MHDs at baseline to < 8 over Weeks 1–12, 71% (170/241) reported < 8 MHDs for the rest of the trial; of those who shifted from > 14 to < 8 MHDs, 66% (49/74) reported < 8 MHDs for the rest of the trial. Reduction to < 8 MHDs was associated with robust improvements in headache intensity and disease burden.

Conclusions

Eptinezumab was associated with sustained reduction in MHD category, with some achieving headache/migraine freedom in patients with a history of preventive treatments that failed. Trial Registration ClinicalTrials.gov (identifier: NCT04418765; https://www.clinicaltrials.gov/ct2/show/NCT04418765 ) and EudraCT (identifier: 2019‐004497‐25; https://www.clinicaltrialsregister.eu/ctr‐search/search?query=2019‐004497‐25 )

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, Monoclonal, HumanizedMigraine DisordersHumansMaleFemaleAdultDouble-Blind MethodMiddle AgedTreatment Outcome

Stichwörter der Autor:innen

anti‐CGRPeptinezumabheadachemigrainepreventive treatment

Substanzen

Antibodies, Monoclonal, Humanizedeptinezumab

Autor:innen und Institutionen

  • Department of Brain and Behavioural Sciences, University of Pavia, Pavia, Italy.
  • IRCCS C. Mondino Foundation, Pavia, Italy.
  • Mayo Clinic Arizona, Scottsdale, Arizona, USA.
  • H. Lundbeck A/S, Copenhagen, Denmark.
  • Lundbeck LLC, Deerfield, Illinois, USA.
  • NIHR King's Clinical Research Facility and Headache Group, King's College London, London, UK.

ORCID-Profile: Cristina Tassorelli, Amaal J Starling, Susanne F Awad, Xin Ying Lee, Line Pickering Boserup, Divya Asher, Seema Soni-Brahmbhatt, Peter J Goadsby

Förderung

  • H. Lundbeck A/S

Zitieren

APA

Tassorelli, C., Starling, A. J., Awad, S. F., Lee, X. Y., Boserup, L. P., Asher, D., Soni-Brahmbhatt, S., Sperling, B., & Goadsby, P. J. (2025). Early and Sustained Shift in Headache Day Frequency Following Eptinezumab Treatment in Adults With Migraine for Whom 2–4 Previous Preventive Treatments Have Failed: A Post Hoc Analysis of the Randomized DELIVER Trial. European Journal of Neurology. https://doi.org/10.1111/ene.70460

Vancouver

Tassorelli C, Starling AJ, Awad SF, Lee XY, Boserup LP, Asher D, et al. Early and Sustained Shift in Headache Day Frequency Following Eptinezumab Treatment in Adults With Migraine for Whom 2–4 Previous Preventive Treatments Have Failed: A Post Hoc Analysis of the Randomized DELIVER Trial. European Journal of Neurology. 2025. doi:10.1111/ene.70460

BibTeX
@article{Tassorelli2025,
  author = {Tassorelli, Cristina and Starling, Amaal J and Awad, Susanne F and Lee, Xin Ying and Boserup, Line Pickering and Asher, Divya and Soni-Brahmbhatt, Seema and Sperling, Bjørn and Goadsby, Peter J},
  title = {Early and Sustained Shift in Headache Day Frequency Following Eptinezumab Treatment in Adults With Migraine for Whom 2–4 Previous Preventive Treatments Have Failed: A Post Hoc Analysis of the Randomized DELIVER Trial},
  journal = {European Journal of Neurology},
  year = {2025},
  doi = {10.1111/ene.70460}
}
Kostenlos starten →